Lv1
30 积分 2021-02-19 加入
HRS-4642: The next piece of the puzzle to keep KRAS in check
3个月前
已完结
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
3个月前
已完结
Mechanisms of NLRP3 inflammasome in rheumatoid arthritis and osteoarthritis and the effects of traditional Chinese medicine
3个月前
已完结
ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models
3个月前
已完结
Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome
3个月前
已完结
Anti-cancer drug molecules targeting cancer cell cycle and proliferation
4个月前
已完结
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
4个月前
已完结
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
4个月前
已完结
Recent advances in the development of EGFR degraders: PROTACs and LYTACs
5个月前
已完结
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
5个月前
已完结
皖公网安备34019202002308
